Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has issued an update.
Alligator Bioscience AB reported significant progress in its clinical and financial endeavors for the period ending September 2025. The company achieved a major milestone with the successful execution of its TO 13 warrant program, raising SEK 28.1 million, and announced promising 30-month survival results for mitazalimab, reinforcing its potential as a transformative treatment for pancreatic cancer. Additionally, Alligator expanded its mitazalimab development through a Phase 2/3 trial for biliary tract cancer and advanced its HLX22 program for HER2-positive gastric cancer. The company also secured a strategic partnership for its RUBY™ bispecific antibody format, showcasing its versatility beyond oncology. Looking ahead, Alligator plans a rights issue to support its financial runway and Phase 3 preparations for mitazalimab.
More about Alligator Bioscience AB
Alligator Bioscience AB is a biotechnology company focused on developing innovative antibody-based therapies, primarily targeting cancer. The company is engaged in advancing its clinical-stage immuno-oncology pipeline, with a particular emphasis on mitazalimab, a promising treatment for pancreatic cancer.
Average Trading Volume: 636,611
Technical Sentiment Signal: Sell
Current Market Cap: SEK132M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.